FTFinancial Times·2dBusiness
score+0.10
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Original
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
“The headline reports a standard corporate acquisition with factual, transactional language, devoid of strong emotional valence.”